|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
1) A larger dose of IFN-alpha does not improve the sustained response rate; however, it may be of benefit in early stages of chronic hepatitis C. 2) Pretreatment, histological stage, and possibly HCV genotype appear to be the main prognostic factors of sustained response.
|
8792690 |
1996 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatitis C virus RNA and long-term response to recombinant interferon-alpha 2b in patients with chronic hepatitis C.
|
7493304 |
1995 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon α2 is an antiviral/antiproliferative protein that is currently used to treat hepatitis C infections and several forms of cancer.
|
28731677 |
2017 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
|
14999598 |
2004 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A 67-year-old man with hepatitis C virus infection and histological features of chronic active hepatitis was treated with human recombinant interferon alpha-2b.
|
10535477 |
1999 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients.
|
28397081 |
2017 |
|
Hepatitis C
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV infection.
|
9097267 |
1997 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A Markov model was developed to estimate costs and quality-adjusted life years (QALYs) comparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin with a usual palliative care for genotype 1 and 6 HCV patients.
|
27492396 |
2016 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
|
7506225 |
1994 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A randomized controlled trial of recombinant interferon alpha-2b in the treatment of Chinese patients with acute post-transfusion hepatitis C.
|
7890900 |
1994 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution.
|
15709027 |
2005 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
A single infliximab dose before pegylated-interferon α2b and ribavirin therapy did not result in greater viral decline during the first 12 weeks of HCV therapy or improved SVR.
|
24212915 |
2014 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 71 treatment-naive HCV RNA-positive patients with biopsy-confirmed chronic hepatitis, with genotype 2b or 3a, viral load < or = 3 million copies per ml and no cirrhosis were randomized to receive either standard interferon therapy (3 MIU interferon-alpha-2a thrice weekly) for 26 weeks or 6 MIU interferon-alpha-2a daily for 4 weeks (induction group) followed by the standard dose (3 MIU thrice weekly) for 22 weeks.
|
11916198 |
2002 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
|
21865660 |
2012 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
ADJ higher doses of RBV based on its early pharmacokinetics-based RBV do not improve SVR rates in HCV GT4 treated in combination with peg-IFN alpha-2-a versus STD therapy.
|
29135370 |
2017 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
|
21791662 |
2011 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Application of response-guided therapy (RGT) rules to the treatment of HCV infection with pegylated interferon-α2a and ribavirin, and direct-acting antivirals (DAAs) such as the NS3/4A protease inhibitors (PIs) boceprevir and telaprevir, relies on the determination of viral genotype and on-treatment HCV RNA level.
|
24941124 |
2015 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
At the end of week 48, HCV RNA was undetectable in 14 of 54 patients (25.9%) receiving pegylated interferon-alpha-2a and in 15 of 54 patients (27.7%) receiving pegylated interferon-alpha-2b.
|
18416586 |
2008 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Baseline Polymorphisms and Emergence of Drug Resistance in the NS3/4A Protease of Hepatitis C Virus Genotype 1 following Treatment with Faldaprevir and Pegylated Interferon Alpha 2a/Ribavirin in Phase 2 and Phase 3 Studies.
|
26195509 |
2015 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Between 1998 and 2007, we treated 36 LT recipients for hepatitis C cirrhosis and subsequent HCV recurrence (27 genotype 1 and 9 genotypes 2/3) with pegylated interferon alpha-2a (180 microg/week), pegylated interferon alpha-2b (1.5 microg/kg per week), or standard interferon alpha-2b (3 MIU 3X/week) plus ribavirin (600-1200 mg/day) for 48 weeks.
|
18617783 |
2008 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Co-infected (n = 13) and mono-infected naïve patients (n = 100) with HCV genotype 2/3 were treated with 135 microg pegylated interferon alpha-2a weekly and weight-based ribavirin daily for 24 weeks.
|
20214543 |
2010 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cohort 2 consisted of 370 Dutch HCV patients of which 252 were part of a clinical trial (treatment with amantadine or placebo, in combination with pegylated interferon alpha-2b and ribavirin) whereas 37 HCV patients received standard therapy.
|
19794310 |
2010 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
|
15876467 |
2005 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Comparing the efficacy of peginterferon alpha-2b plus ribavirin with interferon alpha -2b plus ribavirin in Saudi patients with chronic hepatitis C virus (HCV) commonly infected with genotype 4.
|
15566506 |
2004 |
|
Hepatitis C
|
0.400 |
Biomarker
|
disease |
BEFREE |
Concurrent autoimmune hepatitis and grave's disease in hepatitis C during pegylated interferon α-2a and ribavirin therapy.
|
21912063 |
2012 |